News

Teriflunomide "under the microscope" or what it's like to live with MS in the North

12. 1. 2023 Source: Multiple Sclerosis

The Teri-LIFE study examined teriflunomide very comprehensively. How does it manage to affect the quality of life of patients with multiple sclerosis (MS) according to data from real clinical practice in the Nordic countries? What is adherence to this therapy like? And what are its health-economic consequences? We briefly summarize the answers to these questions.

Cardiovascular Interventions with Continued Therapy with Dabigatran −⁠ Insights from the GLORIA-AF Study

An analysis using data from an international registry of patients with newly diagnosed atrial fibrillation evaluated the safety and efficacy of continued therapy with dabigatran during cardioversion…

12. 1. 2023 Source: Anticoagulant Treatment

Smouldering Multiple Sclerosis: How Can MRI Help in Its Identification?

With the changing understanding of the etiopathogenesis of multiple sclerosis, several new questions arise. One of them is the question of identifying the progressive phase of the disease. Can…

4. 1. 2023 Source: Multiple Sclerosis

Teriflunomide vs. Dimethyl Fumarate: Does Their Classification into Different Treatment Lines Have Merit?

Teriflunomide is one of the first-choice medications in the treatment of multiple sclerosis (MS) patients, not only in the Czech Republic. Conversely, the use of dimethyl fumarate is more limited…

4. 1. 2023 Source: Multiple Sclerosis

Prevalence of Heart Failure and Its Subtypes in the Population of Developed Countries

In developed countries, heart failure occurs in approximately 2% of the population, with an annual incidence of 5-10/1000 inhabitants. The mortality rate for patients with chronic heart failure is…

2. 1. 2023 Source: Heart Failure

Inclisiran −⁠ a new addition to the arsenal of dyslipidemia treatment

At the XXIX Congress of the Czech Society of Internal Medicine ČLS JEP, held November 6−9, 2022 in Prague, lectures on innovative dyslipidemia therapy using the small interfering RNA molecule −…

23. 12. 2022 Source: Chronic Heart Failure and Lipidology

Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention

Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk due to its proven mortality reduction. However, many patients with familial hypercholesterolemia or…

23. 12. 2022 Source: Chronic Heart Failure and Lipidology

Cenobamate −⁠ A Case Study from Slovak Real Practice

Cenobamate is indicated for adjunctive therapy of focal seizures with or without secondary generalization in adult patients who have not achieved sufficient results with previous treatment with at…

23. 12. 2022 Source: Epilepsy

Brigatinib in the Therapy of Pretreated Patients with Advanced ALK-Positive NSCLC

A French study analyzed clinical data of pretreated ALK-positive patients with advanced non-small cell lung cancer (NSCLC) and examined the efficacy of next-generation ALK inhibitors –⁠ brigatinib,…

22. 12. 2022 Source: Non-Small Cell Lung Cancer

Addition of ixazomib to lenalidomide and dexamethasone in multiple myeloma −⁠ Data from real-world Czech practice

A group of Czech and Slovak experts led by Associate Professor Jiří Minařík from the Hemato-Oncology Clinic of the Faculty of Medicine UP and University Hospital Olomouc published the final results…

22. 12. 2022 Source: Hematologic Malignancies

Consolidation therapy with brentuximab vedotin after autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma

At the 12th International Symposium on Hodgkin Lymphoma (ISHL), held in October 2022 in Cologne, results of a Czech study evaluating the efficacy and safety of consolidation therapy with brentuximab…

22. 12. 2022 Source: Hematologic Malignancies

1 … 37 38 39 40 41 … 115

Back Filter by speciality

Remove filters